121 related articles for article (PubMed ID: 10968258)
21. On the molecular basis of the recognition of angiotensin II (AII). NMR structure of AII in solution compared with the X-ray structure of AII bound to the mAb Fab131.
Tzakos AG; Bonvin AM; Troganis A; Cordopatis P; Amzel ML; Gerothanassis IP; van Nuland NA
Eur J Biochem; 2003 Mar; 270(5):849-60. PubMed ID: 12603318
[TBL] [Abstract][Full Text] [Related]
22. Topographic probes of angiotensin and receptor: potent angiotensin II agonist containing diphenylalanine and long-acting antagonists containing biphenylalanine and 2-indan amino acid in position 8.
Hsieh KH; LaHann TR; Speth RC
J Med Chem; 1989 Apr; 32(4):898-903. PubMed ID: 2704034
[TBL] [Abstract][Full Text] [Related]
23. Three-dimensional recognition requirements for angiotensin agonists: a novel solution for an old problem.
Nikiforovich GV; Marshall GR
Biochem Biophys Res Commun; 1993 Aug; 195(1):222-8. PubMed ID: 8363604
[TBL] [Abstract][Full Text] [Related]
24. On the structural basis of the hypertensive properties of angiotensin II: a solved mystery or a controversial issue?
Tzakos AG; Gerothanassis IP; Troganis AN
Curr Top Med Chem; 2004; 4(4):431-44. PubMed ID: 14965310
[TBL] [Abstract][Full Text] [Related]
25. An effort to understand the molecular basis of hypertension through the study of conformational analysis of losartan and sarmesin using a combination of nuclear magnetic resonance spectroscopy and theoretical calculations.
Mavromoustakos T; Kolocouris A; Zervou M; Roumelioti P; Matsoukas J; Weisemann R
J Med Chem; 1999 May; 42(10):1714-22. PubMed ID: 10346924
[TBL] [Abstract][Full Text] [Related]
26. Reciprocal modulation of the binding of angiotensin agonists and antagonists to angiotensin receptors in smooth muscle.
Koziarz P; Beck J; Moore GJ
Gen Pharmacol; 1993 May; 24(3):705-13. PubMed ID: 8365653
[TBL] [Abstract][Full Text] [Related]
27. 1H-NMR studies of [Sar1]angiotensin II conformation by nuclear Overhauser effect spectroscopy in the rotating frame (ROESY): clustering of the aromatic rings in dimethylsulfoxide.
Matsoukas JM; Bigam G; Zhou N; Moore GJ
Peptides; 1990; 11(2):359-66. PubMed ID: 2356159
[TBL] [Abstract][Full Text] [Related]
28. Influence of methylation of the histidine ring of [Sar1]angiotensin II on conformation and biological activity.
Moore GJ; Goghari MH; Franklin KJ
Int J Pept Protein Res; 1993 Nov; 42(5):445-9. PubMed ID: 8106195
[TBL] [Abstract][Full Text] [Related]
29. Angiotensin II vs its type I antagonists: conformational requirements for receptor binding assessed from NMR spectroscopic and receptor docking experiments.
Wilkes BC; Masaro L; Schiller PW; Carpenter KA
J Med Chem; 2002 Sep; 45(20):4410-8. PubMed ID: 12238921
[TBL] [Abstract][Full Text] [Related]
30. Conformational analysis of a highly potent dicyclic gonadotropin-releasing hormone antagonist by nuclear magnetic resonance and molecular dynamics.
Bienstock RJ; Rizo J; Koerber SC; Rivier JE; Hagler AT; Gierasch LM
J Med Chem; 1993 Oct; 36(22):3265-73. PubMed ID: 8230116
[TBL] [Abstract][Full Text] [Related]
31. Correlation of the biological activity and solution conformation of [Asp1,Ile5]- and [Phe4,Tyr8]angiotensin II.
Bleich HE; Freer RJ; Stafford SS; Galardy RE
Proc Natl Acad Sci U S A; 1978 Aug; 75(8):3630-4. PubMed ID: 29291
[TBL] [Abstract][Full Text] [Related]
32. Structural features of angiotensin II which are important for biologic activity.
Peach MJ
Kidney Int Suppl; 1979 Mar; (9):S3-6. PubMed ID: 289861
[TBL] [Abstract][Full Text] [Related]
33. The utility of side-chain cyclization in determining the receptor-bound conformation of peptides: cyclic tripeptides and angiotensin II.
Kataoka T; Beusen DD; Clark JD; Yodo M; Marshall GR
Biopolymers; 1992 Nov; 32(11):1519-33. PubMed ID: 1333831
[TBL] [Abstract][Full Text] [Related]
34. Influence of polyfluorination of the phenylalanine ring of angiotensin II on conformation and biological activity.
Bovy PR; Getman DP; Matsoukas JM; Moore GJ
Biochim Biophys Acta; 1991 Aug; 1079(1):23-8. PubMed ID: 1888761
[TBL] [Abstract][Full Text] [Related]
35. An angiotensin with prolonged action and blood pressure--lowering properties.
Bossé R; Gerold M; Fischli W; Holck M; Escher E
J Cardiovasc Pharmacol; 1990; 16 Suppl 4():S50-5. PubMed ID: 1705628
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and biological activities of angiotensin II and Sarmesin analogues containing cyclohexylalanine.
Hondrelis J; Matsoukas J; Cordopatis P; Ganter RC; Franklin KJ; Moore GJ
Int J Pept Protein Res; 1991 Jan; 37(1):21-6. PubMed ID: 2045217
[TBL] [Abstract][Full Text] [Related]
37. Angiotensin IV is a potent agonist for constitutive active human AT1 receptors. Distinct roles of the N-and C-terminal residues of angiotensin II during AT1 receptor activation.
Le MT; Vanderheyden PM; Szaszák M; Hunyady L; Vauquelin G
J Biol Chem; 2002 Jun; 277(26):23107-10. PubMed ID: 12006574
[TBL] [Abstract][Full Text] [Related]
38. Characterization of a new angiotensin antagonist selective for angiotensin-(1-7): evidence that the actions of angiotensin-(1-7) are mediated by specific angiotensin receptors.
Santos RA; Campagnole-Santos MJ; Baracho NC; Fontes MA; Silva LC; Neves LA; Oliveira DR; Caligiorne SM; Rodrigues AR; Gropen Júnior C
Brain Res Bull; 1994; 35(4):293-8. PubMed ID: 7850477
[TBL] [Abstract][Full Text] [Related]
39. Multiple binding modes for the receptor-bound conformations of cyclic AII agonists.
Plucinska K; Kataoka T; Yodo M; Cody WL; He JX; Humblet C; Lu GH; Lunney E; Major TC; Panek RL
J Med Chem; 1993 Jun; 36(13):1902-13. PubMed ID: 8515427
[TBL] [Abstract][Full Text] [Related]
40. Synthesis, receptor binding affinities and conformational properties of cyclic methylenedithioether analogues of angiotensin II.
Lindman S; Lindeberg G; Gogoll A; Nyberg F; Karlén A; Hallberg A
Bioorg Med Chem; 2001 Mar; 9(3):763-72. PubMed ID: 11310611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
